GlassScriptPhysician profile
Adam Jacob Bennett
NPI 1295184539
$5,173.34
in general payments reported to CMS, 2019-2025
25 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.91 · 2021: $388 · 2022: $825 · 2023: $543 · 2024: $2,267 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,376 · Travel and Lodging: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,376.09 |
| Travel and Lodging | $538.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,842.16 | 2021-2025 | Lensx, Clareon Panoptix Pro, Hydrus Microstent |
| Biotissue Holdings INC. | $769.50 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $295.57 | 2024-2025 | Tecnis Simplicity |
| Mallinckrodt Hospital Products INC. | $284.48 | 2020-2025 | Acthar |
| Glaukos Corporation | $279.00 | 2020-2023 | |
| Ocular Therapeutix, INC. | $242.30 | 2021-2025 | Dextenza |
| Sun Pharmaceutical Industries INC. | $169.34 | 2021-2023 | Cequa |
| Carl Zeiss Meditec, INC. | $159.84 | 2021-2023 | |
| Bausch & Lomb Americas INC. | $142.66 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Rxsight INC | $137.91 | 2022 | |
| Oyster Point Pharma, INC. | $107.21 | 2022-2024 | Tyrvaya, Ryzumvi |
| Coopervision INC. | $106.53 | 2024 | Myday Contact Lens |
| Amgen INC. | $86.14 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $85.76 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $85.34 | 2022-2025 | Oxervate |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $83.61 | 2023-2024 | Vevye |
| Abbvie INC. | $80.85 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Rayner Intraocular Lenses Limited | $45.36 | 2025 | Rayone Spheric, Rayner Cataract Set 1, Rayone Aspheric |
| Novartis Pharmaceuticals Corporation | $38.59 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.29 | 2021 | |
| Ani Pharmaceuticals, INC. | $29.01 | 2025 | Purified Cortrophin Gel |
| Kala Pharmaceuticals, INC. | $22.17 | 2022 | |
| Genzyme Corporation | $20.40 | 2022 | |
| Eyevance Pharmaceuticals LLC | $13.96 | 2022 | |
| Sight Sciences, INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.